Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Prof Angela Russell has been named as a ‘Rising Star’ in the BioBeat 50 Movers and Shakers in BioBusiness 2016 report. Released annually, the report celebrates 50 outstanding women entrepreneurs and business leaders who are recognised for their contributions to global health innovation. BioBeat’s founder Miranda Weston-Smith said that the report highlights those women who are “transforming today’s challenges into tomorrow’s opportunities” and are inspirational “pioneers who are setting the pace in laboratories, healthcare, entrepreneurial companies …“ among others.

Professor Angela RussellAngela Russell, Associate Professor of Medicinal Chemistry at the Departments of Chemistry and Pharmacology at the University of Oxford and co-founder of OxStem Ltd (www.oxstem.co.uk) said “I am delighted to have been recognised in this report standing alongside some exceptional bioscience business leaders in the field.  Our research at OxStem has the potential to impact on the healthcare of millions worldwide with the approach of developing small molecule drugs in a wide range of therapeutic areas including cancer, neurodegenerative diseases and heart failure.  I hope that my nomination, together with the women featured in this report, helps to inspire the next generation of bioscience entrepreneurs”.

The full report can be found at: http://www.mws-consulting.co.uk/wordpress/wp-content/uploads/2015/02/50-Movers-and-Shakers-in-BioBusiness-2016-final.pdf

Similar stories

Crystallography of new drug class facilitates structure-based design

The Potter group, leading an international collaboration, has discovered newly-designed synthetic microtubule disruptors with excellent activities and desirable drug-like profiles. This first example of a new drug class bound to tubulin to be explored crystallographically opens up new avenues for structure-based anti-cancer drug design.